Sjoukje van der Stegen

Statistics

Publications

Citations

158

H-Index

Active since

2011

Affiliations

Fate Therapeutics (United States)(Current)

Memorial Sloan Kettering Cancer Center

Sjoukje van der Stegen is an author at Fate Therapeutics (United States) specializing in immune cell engineering, t cell differentiation, and immunotherapy.

Publications per year

2011–2021

Publications

Trafficking of CAR-Engineered Human T Cells Following Regional or Systemic Adoptive Transfer in SCID Beige Mice

Ana C. Parente‐Pereira, Jerome Burnet, David H. Ellison et al. · Journal of Clinical Immunology · 2011 · 115 citations

Life Sciences, Cell Biology, Immunology +14

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Chia‐Wei Chang, Sjoukje van der Stegen, Mili Mandal et al. · Blood · 2019 · 21 citations

Life Sciences, Immunology, Translational Sciences +16

Clinical Manufacture of FT819: Use of a Clonal Multiplexed-Engineered Master Induced Pluripotent Stem Cell Line to Mass Produce Off-the-Shelf CAR T-Cell Therapy

Xu Yuan, Raedun Clarke, Yi-Shin Lai et al. · Blood · 2021 · 12 citations

Life Sciences, Biotechnology, Immunology +16

Pluripotent Cell-Derived Off-the-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies

Raedun Clarke, Sjoukje van der Stegen, Chia‐Wei Chang et al. · Blood · 2018 · 10 citations

Life Sciences, Biotechnology, Immunology +17

1–4 of 4